DeOndra Dixon INCLUDE Project Act of 2025

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3491 Introduced in House (IH)]

<DOC>

119th CONGRESS
  1st Session
                                H. R. 3491

 To amend the Public Health Service Act to authorize the Secretary of
Health and Human Services to carry out a program of research, training,
  and investigation related to Down syndrome, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 19, 2025

   Ms. DeGette (for herself, Mr. Hudson, Ms. DeLauro, Mr. Cole, Ms.
   Norton, and Mr. Stauber) introduced the following bill; which was
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 To amend the Public Health Service Act to authorize the Secretary of
Health and Human Services to carry out a program of research, training,
  and investigation related to Down syndrome, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``DeOndra Dixon INCLUDE Project Act of
2025''.

SEC. 2. DEONDRA DIXON INCLUDE PROJECT.

    Part B of title IV of the Public Health Service Act (42 U.S.C. 284
et seq.) is amended by adding at the end the following:

``SEC. 409K. DOWN SYNDROME RESEARCH.

    ``(a) In General.--The Director of NIH shall carry out a program of
research, training, and investigation related to Down syndrome to be
known as the `INvestigation of Co-occurring conditions across the
Lifespan to Understand Down syndromE Project' or the `INCLUDE Project'.
    ``(b) Program Elements.--The program under subsection (a) shall
include--
            ``(1) high-risk, high-reward research on the effects of
        trisomy 21 on human development and health;
            ``(2) promoting research for participants with Down
        syndrome across the lifespan, including cohort studies to
        facilitate improved understanding of Down syndrome and co-
        occurring conditions and development of new interventions;
            ``(3) expanding the number of clinical trials that are
        inclusive of, or expressly for, participants with Down
        syndrome, including novel biomedical and pharmacological
        interventions and other therapies designed to promote or
        enhance activities of daily living;
            ``(4) research on the biological mechanisms in individuals
        with Down syndrome pertaining to structural, functional, and
        behavioral anomalies and dysfunction as well as stunted growth;
            ``(5) supporting research to improve diagnosis and
        treatment of conditions co-occurring with Down syndrome,
        including the identification of biomarkers related to risk
        factors, diagnosis, and clinical research and therapeutics;
            ``(6) research on the causes of increased prevalence, and
        concurrent treatment, of co-occurring conditions, such as
        Alzheimer's disease and related dementias and autoimmunity, in
        individuals with Down syndrome; and
            ``(7) research, training, and investigation on improving
        the quality of life of individuals with Down syndrome and their
        families.
    ``(c) Coordination; Prioritizing Nonduplicative Research.--The
Director of NIH shall ensure that--
            ``(1) the programs and activities of the institutes and
        centers of the National Institutes of Health relating to Down
        syndrome and co-occurring conditions are coordinated, including
        through the Office of the Director of NIH and priority-setting
        reviews conducted pursuant to section 402(b)(3); and
            ``(2) such institutes and centers, prioritize, as
        appropriate, Down syndrome research that does not duplicate
        existing research activities of the National Institutes of
        Health.
    ``(d) Consultation With Stakeholders.--In carrying out activities
under this section, the Director of NIH shall, as appropriate and to
the maximum extent feasible, consult with relevant stakeholders,
including patient advocates, to ensure that such activities take into
consideration the needs of individuals with Down syndrome.
    ``(e) Biennial Reports to Congress.--
            ``(1) In general.--The Director of NIH shall submit, on a
        biennial basis, to the Committee on Energy and Commerce and the
        Subcommittee on Labor, Health and Human Services, Education,
        and Related Agencies of the Committee on Appropriations of the
        House of Representatives and the Committee on Health,
        Education, Labor, and Pensions and the Subcommittee on Labor,
        Health and Human Services, Education, and Related Agencies of
        the Committee on Appropriations of the Senate, a report that
        catalogs the research conducted or supported under this
        section.
            ``(2) Contents.--Each report under paragraph (1) shall
        include--
                    ``(A) identification of the institute or center
                involved;
                    ``(B) a statement of whether the research is or was
                being carried out directly by such institute or center
                or by multiple institutes and centers; and
                    ``(C) identification of any resulting real-world
                evidence that is or may be used for clinical research
                and medical care for patients with Down syndrome.''.
                                 <all>